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data, protocol liver biopsies and radiological ﬁndings, in
order to identify patients with rPSC.With this best possi-
ble approach to identify patients with rPSC they found
recurrence of PSC only in patients with active ulcerative
colitis (UC) after OLT. These ﬁndings are consistent with
the fascinating hypothesis of an enterohepatic circulation
of lymphocytes generated in the gut as a concept for the
pathogenesis of PSC. However these results are based
on only 53 patients and – as the authors mentioned – pre-
vious studies including onemeta-analysis [6] did not ﬁnd a
signiﬁcant inﬂuence of UC on rPSC. In terms of method-
ology the study of Cholongitas et al. [5] certainly repre-
sents one of the best approaches to identifying risk
factors for rPSC. Prospective studies of the same quality
level are needed to verify these results.
In summary, in view of the diﬃculties to distinguish
rPSC from other biliary changes after OLT, especially
ITBL, the results of studies on the recurrence of PSC
should generally be considered with a degree of caution.
In the situation of rPSC we are dealing with the allograft
as an immunological and genetically foreign target in an
immunocompromised organism. It would therefore ap-
pear to remain questionable whether ﬁndings regarding
the recurrence of PSC after OLT are directly transfer-
able to our current understanding of the pathogenesis
of PSC in the pre-transplant patient.
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TNF-a could be responsible for disulﬁram-mediated hepatotoxicity
To the Editor:
Current work by Lu et al. [1] showing pyrrolidine
dithiocarbamate-accelerated death of mice with TNF-
a-induced liver injury probably explains for long
known but still not well understood hepatitis in pa-
tients treated with disulﬁram (Antabuse) against
alcoholism.
In these patients, bad prognosis of the disease (even
with a mortality risk of 16%) is associated with ele-
vated bilirubin and aminotransferases level in the liver
[2]. It is symptomatic that TNF-a, when used for sys-
temic anticancer chemotherapy, increased serum levels
of aminotransferases and bilirubin indicating a direct
cytotoxic role of TNF-a in hepatocytes [3]. Further-
more, TNF-a production can be a consequence of
chronic alcoholism even in patients without any liver
disease [4].
TNF-a may not be as toxic for the liver as Lu et al.
claim if it activates not only death signaling through
TNF-α in blood or liver:
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Fig. 1. The proposed mechanism of disulﬁram-induced hepatotoxicity.
[This ﬁgure appears in colour on the web.]
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FADD but also survival signaling through NF-jB
(Fig. 1) [5]. Dithiocarbamates and disulﬁram are potent
NF-jB inhibitors [6], thus their administration in pa-
tients with elevated levels of TNF-a both in the liver
or in the blood can be fatal. Consequently, alcoholics
to be treated by disulﬁram should be screened for
TNF-a in their blood or liver.
References
[1] Lu JW, Wang H, Yan-Li J, Zhang C, Ning H, Li XY, et al.
Diﬀerential eﬀects of pyrrolidine dithiocarbamate on TNF-a-
mediated liver injury in two diﬀerent models of fulminant hepatitis.
J Hepatol 2008;48:442–452.
[2] Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and
prognostic markers in disulﬁram-induced liver injury. J Hepatol
2006;44:791–797.
[3] Bradham CA, Plumpe J, Manns MP, Brenner DA, Trautwein C.
Mechanisms of hepatic toxicity. TNF-induced liver injury. Am J
Physiol 1998;275:G387–G392.
[4] Laso FJ, Vaquero JM, Almeida J, Marcos M, Orfao A. Production
of inﬂammatory cytokines by peripheral blood monocytes in
chronic alcoholism: relationship with ethanol intake and liver
disease. Cytometry B Clin Cytom 2007;72B:408–415.
[5] Micheau O, Tschopp J. Induction of TNF receptor I-mediated apop-
tosis via two sequential signaling complexes. Cell 2003;114:181–190.
[6] Cvek B, Dvorak Z. Targeting of nuclear factor-jB and proteasome
by dithiocarbamate complexes with metals. Curr Pharm Des
2007;13:3155–3167.
Boris Cvek
Palacky University, Hnevotinska 3 Olomouc,
Czech Republic
E-mail address: cvekb@seznam.cz
doi:10.1016/j.jhep.2008.07.001
866 Letters to the Editor / Journal of Hepatology 49 (2008) 862–866
